Avantor, Inc.: management transactions · United States · SEC (Form 4)

About Avantor, Inc.

Avantor, Inc. (NYSE: AVTR) is a U.S.-based global provider of mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania, in the United States, and its heritage dates back to 1904 through the founding of J.T. Baker Chemical Company. That long operating history matters because Avantor is not a drug developer; it is an enabling platform that supplies the tools, materials and workflow support used across research, development and biomanufacturing. For investors, that makes Avantor a classic “picks-and-shovels” name tied to the broader innovation economy in healthcare and industrial science. Avantor’s business model is organized around two reportable segments: Laboratory Solutions and Bioscience Production. Laboratory Solutions serves a broad customer base spanning research laboratories, academic institutions, healthcare settings and selected industrial applications. The segment provides a wide range of consumables, chemicals, specialty materials, workflow solutions and services used in day-to-day scientific operations. Bioscience Production focuses on the products and services needed in biopharma manufacturing, including high-purity materials, process consumables and solutions used in biologics, cell and gene therapy, and other regulated production environments. Together, these segments position Avantor both at the discovery end of science and at the production end where scale, quality and reliability are critical. Competitively, Avantor stands out for the breadth of its portfolio, its global distribution footprint and its ability to supply mission-critical items that customers need continuously. The company reports activity across more than 180 countries and serves a very large installed customer base. This scale is strategically important because recurring, high-friction laboratory and production inputs can create sticky customer relationships, especially when quality, traceability and regulatory compliance are central to the buying decision. Avantor’s key offerings include laboratory consumables, reagents, chemicals, high-purity materials, bioprocessing supplies, and a growing set of value-added services. The company has also emphasized centralized service centers and localized quality-control capabilities, which can help customers reduce operational complexity and free up laboratory space and staff for higher-value work. In that sense, Avantor competes not only on products but on workflow efficiency and service integration. Recent corporate developments point to an active operational and innovation agenda. In 2025 and 2026, Avantor announced initiatives around digital traceability for smart consumables, CAR-T manufacturing support, next-generation sterile sampling solutions, and expanded microbial and stability testing capacity in the United States. Its latest quarterly commentary in 2026 highlighted stable top-line performance, with management focusing on execution, productivity and operational improvement. Overall, Avantor remains a globally diversified life-science tools platform listed on the NYSE in the United States, with exposure to structurally attractive end markets but some sensitivity to customer spending cycles and execution discipline.